Strategies to Overcome Challenges in Commercializing Treatments for Rare Diseases

By Kelly Cockerill, Vice President, Marsha Pelletier, Director, Philippe De Gaiffier, Consultant, and Carrie Jones, Partner

Rare Disease Day serves as a reminder of the ongoing collaborative effort in the healthcare industry to bring valuable new treatments for the over 300MM global rare disease patients.

Despite the rapidly advancing science and established unmet need for patients, rare disease drug manufacturers face several unique challenges when commercializing new products.

Health Advances, as a strategic healthcare and life sciences consulting firm, helps rare disease drug developers make smart decisions that will best position their products for broad patient access. 

In our 30 years of work across the rare disease industry, we’ve identified several key success factors:

Rare Diseases

 

Interested in some of these examples? Please reach out to us or follow our blog so you don’t miss our future deep dives on these topics above and many more. https://healthadvancesblog.com

Contact

Carrie Jones cjones@healthadvances.com, Partner leads Health Advances’ Rare and Orphan Disease Practice.

###

 

 

Return to Insights Center

Related Insights

Podcast

De-risking Drug Development | Episode 3: Plan how to get to market quickly, post proof-of-concept

Jul 16, 2024

Blog

End-to-end risk management: Getting the most from your program

Apr 4, 2022

Blog

Adapting drug supply strategies to modern study models

Jun 1, 2022

Video

Why Biotech Matters More Than Ever

Jun 1, 2022

Blog

Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions

May 16, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Podcast

Decentrally Speaking | Episode 2: The Shifting Roles of Pharmaceutical Depots within a Decentralized Trial Environment

May 9, 2022

Article

Digital Health in Japan and Korea – Where Is It Heading?

May 4, 2022

Blog

Patient Advocacy Groups: A vital partner for sponsors that understand how to engage with patients

May 3, 2022

Blog

Patients as Partners 2022: Moving from Insights to Action

May 3, 2022

Article

Opportunities and Challenges for Drug Makers in MDD

May 2, 2022

Blog

Toward more inclusive studies: Reaching and retaining patients from underrepresented communities

Apr 25, 2022